Companies › Laekna
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Metabolic and endocrine, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Afuresertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 3 | Breast Cancer | Dec 2026 |
| LAE102 | – | Phase 1 | Overweight and Obese Volunteers; Overweight and Obesity | Mar 2028 |
| LAE103 | – | Phase 1 | Overweight and Obesity | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06493084 | LAE102 | Phase 1 | Overweight and Obese Volunteers | Metabolic and endocrine | Sep 2026 |
| NCT04851613 | Afuresertib | Phase 3 | Breast Cancer | Oncology | Dec 2026 |
| NCT07230496 | LAE102 | Phase 1 | Overweight and Obesity | Metabolic and endocrine | Mar 2028 |
| NCT07230496 | LAE103 | Phase 1 | Overweight and Obesity | Metabolic and endocrine | Mar 2028 |
AstraZeneca Merck & Co. (MSD) Roche Alterome Therapeutics Zhejiang Haichang Biotech Atavistik Bio
JCR Pharmaceuticals Zhejiang Haichang Biotech Ascletis Pharma (China) The United Bio-Technology (Hengqin) BrightGene Bio-Medical Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.